SARS-CoV-2 Antibodies and Immunity: Still to Explore for COVID-19

Ashok Chakraborty¹* and Anil Diwan²

Received: July 27, 2022;   Published: August 10, 2022

DOI: 10.26717/BJSTR.2022.45.007229

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

SARS-CoV-2 is one of the known beta family members of human coronaviruses, like HCoV-HKU1, SARS-CoV-2, MERS-CoV and SARS-CoV. SARS family viruses cause severe respiratory disease in humans. SARS-CoV-2 has recently considered as a pandemic with over 100 M confirmed cases and over 1.5 M death worldwide. Vaccines and antibodies appeared as record pace. However, generation of variants has already been demonstrated as an escape of virus from a particular vaccine therapy. Therefore, a broad-spectrum anti-CoV therapies should be emphasized over antibody therapy.

Keywords: COVID-19; SARS-CoV-2; Vaccine; Antibodies; Biopolymer; NV-CoV-2; Antiviral

Abbrevations: CoV: Coronavirus; CsA: Cyclosporin A; DMV: Double Membrane Vesicles; FDA: Food And Drug Administration; hAPN: Human Aminopeptidase N; HAT: Human Airway Trypsin-Like Protease; ORF: Open Reading Frame; SARS: Severe Acute Respiratory Syndrome; IFN: Interferon; IBV: Infectious Bronchitis Virus; hDPP4: Human Dipeptidyl Peptidase 4; MERS: Middle East Respiratory Syndrome; NHP: Non-Human Primate; TMPRSSII: Transmembrane Protease; HCoV: Human Coronavirus; RBD: Receptor Binding Domain; hACE2: Human Angiotensin Converting Enzyme 2; RNA: Ribonucleic Acid